Wanbury Limited (BOM:524212)
193.00
+6.45 (3.46%)
At close: Oct 16, 2026
Wanbury Revenue
Wanbury had revenue of 1.66B INR in the quarter ending June 30, 2026, with 1.47% growth. This brings the company's revenue in the last twelve months to 6.53B, up 3.34% year-over-year. In the fiscal year ending March 31, 2026, Wanbury had annual revenue of 6.50B with 8.47% growth. That makes Wanbury the 25,522nd largest company in the world by revenue and 1,580th in India.
Revenue (ttm)
6.53B
Revenue Growth
+3.34%
P/S Ratio
1.03
Revenue / Employee
5.44M
Employees
1,200
Market Cap
6.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.50B | 507.54M | 8.47% |
| Mar 31, 2025 | 6.00B | 217.77M | 3.77% |
| Mar 31, 2024 | 5.78B | 780.91M | 15.63% |
| Mar 31, 2023 | 5.00B | -115.39M | -2.26% |
| Mar 31, 2022 | 5.11B | 1.19B | 30.23% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anuh Pharma | 7.79B |
| Sudarshan Pharma Industries | 7.32B |
| Lincoln Pharmaceuticals | 6.94B |
| ZIM Laboratories | 3.97B |
| Albert David | 3.64B |
| Bharat Parenterals | 3.23B |
| Kilitch Drugs (India) | 2.37B |
| Medicamen Biotech | 2.06B |
Wanbury News
- 4 months ago - Wanbury successfully clears TGA inspection at Tanuku API facility - Business Upturn
- 8 months ago - Wanbury begins commercial production of high-potent anaesthetic API - Business Upturn
- 1 year ago - Wanbury implements SAP S/4HANA ERP to drive future ready operations - Business Upturn
- 1 year ago - Wanbury launches next-gen iron supplement ‘C RED’ to revolutionize anemia management in India - Business Upturn
- 1 year ago - Wanbury receives GMP certification from ANVISA for Patalganga facility - Business Upturn
- 1 year ago - Wanbury’s Tanuku facility in Andhra Pradesh completes ANVISA inspection with zero observations - Business Upturn
- 1 year ago - Wanbury launches Wanbury C-RED and Ketamine Hydrochloride - Business Upturn
- 1 year ago - Wanbury shares rise 2.56% following company refinances Rs 95 crore NCDs, reducing interest costs - Business Upturn